Core Viewpoint - The light industry and beauty care sector is expected to stabilize and improve by 2026, driven by domestic demand policies and steady export growth, despite facing certain pressures in the broader environment [2] Domestic Demand - The "14th Five-Year Plan" year is anticipated to see an increase in domestic demand policies, coupled with a growing consumer pursuit of high-quality living, which opens up significant growth opportunities for the industry [2][3] Export Potential - The cross-border e-commerce penetration rate has substantial room for improvement, and the improvement of international relations along with the demand boost from emerging markets will further expand the market, injecting momentum into the industry's overseas expansion [2][3] Company Insights - Companies with core technology and brand advantages are expected to seize opportunities, with cutting-edge technology enhancing product competitiveness and brand strength breaking the price-performance competition [2] - These companies are likely to benefit from domestic demand and explore overseas markets through global layouts, leading the growth in the trend of high-quality industry development [2] Investment Focus - **Beauty Sector**: Focus on high-end skincare and makeup brands with Eastern cultural characteristics such as Maogeping (01318) and Lin Qingxuan (02657), as well as companies like Marubi Biotechnology (603983.SH) showing marginal improvements [3] - **Home Furnishing**: Attention on leading companies with strong channel capabilities and multi-category layouts like Oppein Home Group (603833.SH) and Kuka Home (603816.SH), as well as Man Wah Holdings (01999) benefiting from the anticipated recovery in the US real estate market due to Federal Reserve rate cuts [3] - **Two-Wheel & Motorcycle**: The two-wheeler market is generally stable with a natural replacement cycle, and companies like Yadea Technology (01585), Aima Technology (603529.SH), and Ninebot (689009.SH) are under focus as market expectations are currently pessimistic [3] Light Industry Consumption - **Personal Care**: Companies with a big product strategy and all-channel expansion capabilities such as Baiya Co., Ltd. (003006.SZ) and Weigao Medical (300888.SZ) are noteworthy [4] - **Stationery**: Product and channel optimization are key for stationery companies adapting to current consumer trends, with attention on Morning Glory (603899.SH) and Qixin Group (002301.SZ) [4] Jewelry Sector - Focus on Laopu Gold (06181), which is expected to see performance growth due to continuous channel expansion and market breakthroughs [5] Export Companies - Companies with significant technical barriers and brand advantages in high-demand segments such as Haoyang Co., Ltd. (300833.SZ) and Yiyi Co., Ltd. (001206.SZ) are of interest [5]

Investment Rating - The report indicates that the cosmetics and medical beauty sector is currently underperforming compared to the market, with the Shenwan Beauty Care Index rising by 2.6% from December 31, 2025, to January 9, 2026, which is lower than the overall market performance [1][2]. Core Insights - 毛戈平 has initiated an international strategic partnership with L Catterton, a leading global consumer investment firm, focusing on global market expansion, acquisitions, strategic investments, capital structure optimization, and talent introduction [1][6][17]. - The approval of products such as 爱美客's botulinum toxin and 奇璞生物's collagen implant signifies ongoing advancements in the medical beauty supply chain, enhancing competitive diversity for 2026 [1][6][18][19]. - The report highlights the robust foundation of 壹网壹创's e-commerce operations, leveraging AI to enhance performance and expand its market reach, particularly in the consumer goods sector [1][7][8][10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with specific indices underperforming against the Shenwan A Index [2][4]. - The top-performing stocks in the sector include 力合科创 (+14.7%), 毛戈平 (+8.6%), and 水羊股份 (+7.6%), while the underperformers include 嘉亨家化 (-3.9%) and 百亚股份 (-2.8%) [2][5]. Recent Developments - 毛戈平's strategic collaboration with L Catterton aims to enhance its brand's presence in high-end retail channels globally and establish a joint investment fund focused on premium beauty products [1][6][17]. - The approval of 爱美客's botulinum toxin and 奇璞生物's collagen implant reflects a significant push in the medical beauty equipment supply chain, contributing to competitive advantages in the upcoming year [1][6][18][19]. E-commerce Insights - 壹网壹创's e-commerce operations are well-established, with a comprehensive coverage of consumer goods categories and a strong partnership with Alibaba, which is expected to drive revenue growth through AI integration [1][7][8][10]. - The e-commerce sector is witnessing a resurgence in attention, with Alibaba's platform traffic rebounding, indicating a potential recovery in the performance of e-commerce operations [1][8][10]. Market Data - The report notes that the retail sales of cosmetics in China for November 2025 grew by 6.1%, supported by promotional events like Double 11, indicating a robust recovery in consumer spending [13][15]. - The overall retail sales of consumer goods in China reached 45.6 trillion yuan in the first eleven months of 2025, with a year-on-year growth of 4.0% [13][15].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [2][3]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance than the market, with the Shenwan Beauty Care Index rising by 2.6% from December 31, 2025, to January 9, 2026, which is lower than the Shenwan A Index by 2.8 percentage points [3][4]. - 毛戈平 has initiated an international strategic partnership with L Catterton, focusing on global market expansion, acquisitions, and strategic investments, which is expected to enhance its high-end retail channels and operational optimization [9][21]. - Recent approvals for products such as 爱美客's botulinum toxin and 奇璞生物's collagen implant highlight the ongoing advancements in the medical beauty supply chain, supporting diversified competition in 2026 [9][22][23]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with specific indices showing lower growth rates compared to the overall market [3][4]. - The top-performing stocks in the sector include 力合科创 (+14.7%), 毛戈平 (+8.6%), and 水羊股份 (+7.6%), while the worst performers were 嘉亨家化 (-3.9%) and 百亚股份 (-2.8%) [5]. Recent Developments - 毛戈平's strategic partnership with L Catterton aims to enhance its brand's global presence and operational capabilities [9][21]. - The approval of 爱美客's botulinum toxin and 奇璞生物's collagen implant signifies a robust supply chain in the medical beauty sector [22][23]. Investment Recommendations - Recommended companies include 毛戈平, 上美股份, and 上海家化 for their strong brand matrices and growth potential. Companies like 爱美客 and 朗姿股份 are highlighted for their strong profitability and product pipeline [3][10]. - The report suggests focusing on companies with high R&D barriers and strong profitability in the upstream medical beauty segment [3][10].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights the successful IPO of Shaanxi Tourism, which leverages its rich tourism resources and strong operational experience to build competitive advantages through a combination of performance-driven tourism, cable car operations, and dining services [22][24][34] - The report emphasizes the resilience of the cultural tourism industry amid ongoing trends to expand domestic demand and promote consumption, suggesting that Shaanxi Tourism's future growth will be supported by new performance projects and cable car capacity upgrades [36] Summary by Sections Retail and Social Services Market Review - The retail and social services indices rose by 4.23% and 4.71% respectively during the week of January 5 to January 9, 2026, with the Shanghai Composite Index increasing by 3.82% [12][14] - Among the sub-sectors, the supermarket segment showed the highest growth, with an increase of 8.18% year-to-date [15][17] Industry Dynamics: Shaanxi Tourism - Shaanxi Tourism, a leading regional tourism company, successfully listed on the Shanghai Stock Exchange on January 6, 2026, becoming the first A-share listed company of the year [22] - The company reported significant revenue contributions from its tourism performance and cable car operations, with a net profit margin and gross profit margin remaining high post-pandemic [24][27] - Revenue breakdown for the first half of 2025 shows that tourism performance accounted for 60.2%, cable car operations for 35.8%, and dining services for 4.0% [24] Investment Recommendations - The report recommends focusing on high-end gold and fashion jewelry brands, highlighting companies like Chow Tai Fook and Chao Hong Ji, which are expected to benefit from market trends [39] - It also suggests monitoring offline retail companies adapting to market changes and AI-enabled cross-border e-commerce leaders, with specific recommendations for Yonghui Supermarket and Aiying Room [39] - In the cosmetics sector, the report emphasizes brands that capture emotional value and innovate with safe ingredients, recommending companies like Mao Ge Ping and Proya [40]

Medical Aesthetics - Jiangsu Chuangjian Medical Technology Co., Ltd. received approval for its cross-linked recombinant collagen implant, marking a significant development in the medical aesthetics market [2][17] - The product is designed for facial dermal tissue filling to correct moderate to severe dynamic wrinkles, making it the fifth recombinant collagen implant approved in China and the first cross-linked version [17] - The recombinant collagen industry is shifting from "single type" to "diverse structure," with companies accelerating competition towards full-scenario applications [18] Cosmetics - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, officially listed on the Hong Kong Stock Exchange, becoming the first high-end domestic skincare brand to go public [3][19] - The company has established a comprehensive supply chain system and a unique OMO (Online-Merge-Offline) channel model, which integrates online and offline sales to enhance customer engagement and drive growth [23][35] - Lin Qingxuan's flagship product, the camellia oil essence, has achieved a leading repurchase rate of 33.5% in the industry, indicating strong customer loyalty [27][46] Investment Recommendations - The company recommends focusing on differentiated upstream medical aesthetics product manufacturers and chain medical institutions, highlighting the potential of Meili Tianyuan Medical Health [4][48] - In the cosmetics sector, the emphasis is on domestic brands that innovate in emotional value and safe ingredients, with key recommendations including Lin Qingxuan and other brands that leverage both online and offline channels [4][47] Market Performance - In December, the beauty and personal care index fell by 1.70%, underperforming the broader market, while the medical aesthetics sector saw notable gains from companies like Meili Tianyuan Medical Health and Jinbo Biological [5][10] - For the full year of 2025, the medical aesthetics sector showed mixed performance, with companies like Sihuan Pharmaceutical and Yonghe Medical leading in growth [10] Financial Highlights - Lin Qingxuan reported a total revenue of 1.05 billion yuan in the first half of 2025, reflecting a year-on-year growth of 98.3%, primarily driven by its camellia oil essence [23][41] - The company's gross margin remains high at 82.4%, with specific product categories like essence oil achieving even higher margins [23][41]

Group 1 - The report highlights that the service industry is increasingly merging with technology, leading to the emergence of top-tier listed companies in sectors such as fintech, logistics, enterprise services, and healthcare [2][10] - Countries are exploring unique paths to develop their service industries, with examples including the U.S. focusing on fintech innovation, Germany emphasizing industrial design, and Singapore building digital infrastructure [2][10] - China's national strategy aims to enhance service industry capacity and quality through targeted policies, including the removal of entry barriers in key sectors like telecommunications and healthcare [2][39] Group 2 - The report identifies three main investment directions in the service industry: productive services, lifestyle services, and emerging services [2][45] - Productive services are seen as a core engine, with sectors like testing, industrial software, and financial services highlighted for their growth potential [2][3][45] - Lifestyle services are focused on improving living standards and consumption upgrades, with high growth observed in areas such as gaming, aviation, and tourism [3][45] Group 3 - Emerging services are positioned as key to cultivating new productive forces, with rapid developments in AI and the integration of healthcare and pharmaceutical services [4][45] - The report emphasizes the importance of cross-border e-commerce as a new growth driver for foreign trade, leveraging China's supply chain advantages [4][45] - Specific companies such as Cintas and CVS Health are cited as examples of successful service firms in the U.S., showcasing effective business models and market strategies [1][15][18]

Investment Rating - The industry investment rating is "Positive" (首次) [1] Core Insights - The beauty and personal care industry is experiencing a mixed performance, with the beauty care index declining by 1.70% in December 2025, ranking 24th among all primary industries [15] - The medical beauty sector is seeing innovation with the approval of new products, such as the cross-linked recombinant collagen implant by Jiangsu Chuangjian Medical Technology Co., which is expected to inject new momentum into the market [7][34] - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic high-end skincare brands [8][39] Summary by Sections Market Review - In December, the beauty care index reported a decline of 1.70%, underperforming the broader market, which saw the Shanghai Composite Index increase by 2.06% [15] - For the entire year of 2025, the beauty care index showed a cumulative increase of 0.39%, again lagging behind the Shanghai Composite Index's 18.41% growth [15] Medical Beauty - Jiangsu Chuangjian Medical's cross-linked recombinant collagen implant has been approved, making it the fifth such product in China and the first cross-linked version [34] - The industry is shifting from single product competition to a full-chain layout, with companies like Jinjian Biological and Junzi Biological also making significant advancements in the recombinant collagen space [34][36] Cosmetics - Lin Qingxuan has established itself as a leader in the high-end domestic skincare market, achieving the highest retail sales among domestic brands in 2024 [39] - The company has built a comprehensive supply chain and employs an OMO (Online-Merge-Offline) model to enhance customer engagement and sales [39][49] - Lin Qingxuan's core product, the camellia oil essence, has a high repurchase rate of 33.5%, indicating strong customer loyalty [51] Investment Recommendations - The report recommends focusing on differentiated upstream medical beauty product manufacturers and chain medical beauty institutions, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][53] - In cosmetics, the report suggests investing in brands that innovate in emotional value and safe ingredients, with a focus on domestic brands like Maogeping and Lin Qingxuan [54]

Core Viewpoint - The approval of the injectable type A botulinum toxin product from Huons BioPharma marks a significant milestone for the company, enhancing its strategic positioning in the competitive Chinese medical aesthetics market, which is characterized by a growing number of similar products [2][3]. Group 1: Company Developments - The company has been seeking new growth avenues beyond its core hyaluronic acid business, with the injectable botulinum toxin being one of its earliest product initiatives [2]. - The company signed an exclusive agency agreement with Huons Global in September 2018, which was later deepened by acquiring a 25.4% stake in Huons BP in June 2021 [3]. - The recent approval is expected to enrich the company's product matrix and allow for comprehensive solutions for clients, aligning with market expectations for product pricing and positioning [3][6]. Group 2: Market Context - The Chinese medical aesthetics market has seen significant changes over the past seven years, with the number of approved botulinum toxin products increasing to seven, including the newly approved product from Huons BP [7]. - The market was previously dominated by two brands, Botox and Hengli, which held a combined market share of 100% until recent years [7]. - The current market dynamics indicate that while new entrants may face challenges due to intense competition and price pressures, there is still potential for growth, particularly in the mid-to-high-end market segment [9]. Group 3: Stock Market Reaction - Following the announcement of the product approval, the company's stock price rose by 2.69%, reflecting positive market sentiment [5].

证券日报网讯 1月9日，爱美客（300896）在互动平台回答投资者提问时表示，医美行业正从高速增长 向高质量发展转型，各项监管新政策的出台有利于加速行业洗牌与合规化进程。企业竞争不只是产品价 格的竞争，还包括品牌、技术与服务、行业整合能力等因素。公司将通过不断提升核心竞争力，优化客 户服务，推进公司业务的稳定可持续发展。 ...

（文章来源：证券日报） 证券日报网讯 1月9日，爱美客在互动平台回答投资者提问时表示，公司注射用A型肉毒毒素在韩国市场 已积累多年临床应用数据，其临床安全与稳定性得到了市场的验证，该产品通过与公司现有产品的组 合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞争力。 ...